<?xml version="1.0" encoding="UTF-8"?>
<ref id="B25-pharmaceuticals-12-00060">
 <label>25.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Chang</surname>
    <given-names>A.Y.</given-names>
   </name>
   <name>
    <surname>Lynch</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Martins</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Encinales</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Cadena Bonfanti</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Pacheco</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Reid</surname>
    <given-names>S.P.</given-names>
   </name>
   <name>
    <surname>Lara Sarabia</surname>
    <given-names>O.E.</given-names>
   </name>
   <name>
    <surname>González Torres</surname>
    <given-names>H.J.</given-names>
   </name>
   <name>
    <surname>Mejia Castillo</surname>
    <given-names>S.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Long-term clinical outcomes of Zika-associated Guillain-Barré syndrome</article-title>
  <source>Emerg. Microbes Infect.</source>
  <year>2018</year>
  <volume>7</volume>
  <fpage>4</fpage>
  <lpage>7</lpage>
  <pub-id pub-id-type="doi">10.1038/s41426-018-0151-9</pub-id>
  <pub-id pub-id-type="pmid">29323108</pub-id>
 </element-citation>
</ref>
